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is the recent finding that demethylation 
at the FOXP3 promoter site can be used 
to discriminate true Tregs from activat-
ed nonregulatory T cells (Baron et al., 
2007; Janson et al., 2008).
There have been conflicting reports 
regarding the role of Tregs in cutaneous 
T-cell lymphoma (CTCL). A report that 
malignant T cells from CTCL patients 
stimulated in vitro with immature den-
dritic cells loaded with apoptotic T-cell 
debris adopted a Treg-like phenotype 
led to assertions that CTCL was a malig-
nancy of Tregs (Berger et al., 2005). 
However, even normal T cells cocul-
tured with immature dendritic cells 
presenting peptides from apoptotic 
cells have been shown to adopt a regu-
latory T-cell phenotype (Steinman et al., 
2003). This is a major mechanism for 
the formation of peripheral tolerance, 
one that may explain maternal fetal 
tolerance and that is currently being 
evaluated for the treatment of allograft 
rejection (Adams et al., 2007; Morelli 
and Thomson, 2007). Subsequent histo-
logic studies found low or negative 
expression of FOXP3 in the malignant 
T cells of CTCL skin lesions (Gjerdrum 
et al., 2007). However, CTCL skin 
lesions did contain benign infiltrating 
FOXP3+ Tregs, and increased numbers 
of benign Tregs were associated with 
improved survival. A second study 
found no evidence for preferential 
FOXP3 expression among malignant T 
cells in the skin lesions of Sézary syn-
drome; instead, an overall reduction in 
FOXP3+ Treg numbers in both the skin 
and the blood of Sézary patients was 
reported (Klemke et al., 2006). Studies 
of peripheral blood in advanced-stage 
CTCL have found no clear differences 
in blood Treg numbers in CTCL patients 
versus normal controls, but Tregs in 
patients with high tumor burdens 
showed decreased suppressive function 
(Tiemessen et al., 2006).
Taken together, these studies suggest 
that Treg function is not always a feature 
of the malignant T cells in CTCL and 
that maintenance of normal Treg func-
tion may actually be a positive prog-
nostic indicator. Recent findings that 
extracorporeal photopheresis increases 
Treg numbers in patients with CTCL, as 
it does in other inflammatory diseases, 
support this observation (Shiue et al., 
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By virtue of their ability to inhibit T-cell 
activation, proliferation, cytokine pro-
duction, and cytotoxicity, regulatory 
T cells (Tregs) can suppress local 
immune reactions (Sakaguchi, 2005). 
Tregs play a critical role in inducing 
and maintaining immune self toler-
ance; humans and mice with mutations 
in the Treg associated transcription fac-
tor FOXP3 gene lack functional Tregs 
and develop widespread and lethal 
automimmunity (Bacchetta et al., 2006; 
Brunkow et al., 2001; Khattri et al., 
2003; Powell et al., 1982; Satake et al., 
1993). In addition to their normal role 
in maintaining self-tolerance, Tregs are 
either expanded or locally recruited 
in many human cancers, where they 
impair antitumor immunity (Baecher-
Allan and Anderson, 2006).
Despite their functional importance, 
identification of Tregs can be problem-
atic. Both Tregs and recently activated 
T cells express the high-affinity IL-2 
receptor chain CD25, making it impos-
sible to discriminate Tregs from recently 
activated T cells using this marker alone. 
Tregs can be identified definitively by 
demonstrating their functional ability 
to suppress T-cell proliferation in vitro. 
However, Tregs are often present in 
low numbers, making functional assays 
difficult or impossible. The next most 
reliable method of identifying Tregs is 
by demonstrating high and constant 
expression of the transcription factor 
FOXP3, which is critical for their devel-
opment and functional activity. As noted 
previously, mutations in this gene lead 
to decreased regulatory T-cell function 
in both mice and humans, and expres-
sion levels of the FOXP3 protein corre-
late with the suppressive ability of Tregs 
(Fontenot et al., 2003; Tao et al., 2007). 
In mice, FOXP3 is expressed exclu-
sively by Tregs. In humans, FOXP3 is 
transiently expressed by all T cells after 
activation, although expression levels 
do not reach those observed in true 
Tregs (Clark and Kupper, 2007; Gavin 
et al., 2006; Pillai et al., 2007). Before 
this biology was fully understood, small 
increases in FOXP3 protein expression 
or mRNA levels were misinterpreted 
as indicating a Treg phenotype. One 
bright spot in the field of Treg biology 
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2009). However, one recent study 
did find convincing Treg function 
in the malignant T cells from a sub-
set of patients with Sézary syndrome. 
Malignant T cells in these patients pro-
duced IL-10 and transforming growth 
factor-β and could suppress T-cell prolif-
eration in vitro (Krejsgaard et al., 2008). 
Interestingly, suppressive function in 
these cells differed from that of normal 
Tregs in that it was driven by Jak3/STAT5 
signaling as opposed to FOXP3. In 
short, there are conflicting findings as to 
whether CTCL represents a malignancy 
of Tregs and, indeed, whether Treg func-
tion is part of the problem in CTCL or 
part of the solution.
Heid et al. (2009, this issue) have 
convincingly demonstrated that the 
malignant T cells in a subset of Sézary 
patients are true FOXP3+ Tregs. 
Malignant T cells in these patients 
expressed elevated levels of both FOXP3 
mRNA and protein, had demethylation 
at the FOXP3 promoter locus, and, most 
critically, were able to suppress the pro-
liferation of other T cells in vitro.
Ongoing controversies in CTCL 
aside, most groups would agree that 
CTCL is a malignancy of T cells that 
home to and populate the skin. Normal 
human skin is populated by 20 billion 
T cells (Clark et al., 2006). Of these, 
70–80% are diverse, polarized effec-
tor memory T cells, including T helper 
type 1 (Th1), Th2, and Th17 cells, as 
well as recently described populations 
of T cells producing IL-13 (Calarese et 
al., 2009) and TNF-α alone (Clark et 
al., 2009). Only 5–10% of the T cells 
in normal human skin are FOXP3+ 
Tregs (Clark and Kupper, 2007). These 
cells show high and stable expression 
of FOXP3 and suppress the prolifera-
tion of autologous T cells in vitro. Skin 
resident effector T cells lack expression 
of the lymph node homing addressins 
CCR7 and L-selectin and thus would 
be expected to be excluded from 
lymph nodes (Clark et al., 2006). 
Moreover, few are found in blood 
(Campbell et al., 2001). Elegant stud-
ies in mice have recently shown that 
skin resident effector memory T cells 
not only survive long-term within the 
skin but also remain in a fixed location 
(Gebhardt et al., 2009). This character-
istic may explain why lesions of fixed 
drug eruption (which are infiltrated by 
IFN-γ-producing T cells) and psoriasis 
lesions (infiltrated by Th17 cells) remain 
in fixed locations and tend to recur at 
the same sites when suppressive thera-
py is discontinued (Lowes et al., 2008; 
Teraki and Shiohara, 2003). In contrast 
to these populations of effector and 
regulatory T cells, the remaining 20% 
of T cells in human skin coexpress skin 
homing addressins (CLA, CCR4) as 
well as lymph node homing addressins 
(CCR7 and L-selectin). Coexpression 
of L-selectin and CCR7 has been used 
to identify central memory T cells, a 
type of T cell found in high numbers 
in blood and thought to represent a 
long-term repository for immunologic 
memory (Campbell et al., 2001). The 
addressin expression pattern of these 
normal skin T cells suggests they are 
an intermediate phenotype capable of 
accessing the skin, blood, and second-
ary lymphoid organs.
Human skin therefore contains 
20 billion T cells that are exposed 
throughout our lives to multiple 
insults, including environmental tox-
ins, UV light, and potentially muta-
genic viral infections. Studies using 
spectral karyotyping, comparative 
genomic hybridization, and TCR-γ 
chain rearrangements have demon-
strated that chromosomally abnormal 
T cells are present in the skin lesions 
of even the earliest stages of CTCL and 
that in later stages in which malignant 
T cells can be clearly identified, these 
genetically damaged cells are identi-
cal to those bearing the clonal malig-
nant TCR (Kaltoft et al., 1994; Marcus 
Muche et al., 2004; Padilla-Nash et 
al., 2007; Whang-Peng et al., 1982). 
Thus, even in its earliest stages, CTCL 
is a malignancy of genetically unsta-
ble, chromosomally damaged T cells 
(Thestrup-Pedersen and Kaltoft, 1994). 
Given the mixed population of T cells 
in skin, it should not be surprising that 
one observes a range of phenotypes 
depending on the characteristics of 
the transformed cell type. Malignantly 
transformed cells often maintain some 
characteristics of their benign precur-
sors. For example, T cells in stable 
patch plaque CTCL lack expression of 
CCR7, L-selectin, and CD27, all char-
acteristics of polarized effector memo-
ry T cells (Campbell et al., 2009). The 
fact that malignant T cells in mycosis 
fungoides are found only in skin and 
often remain localized for decades to 
fixed plaques is consistent with the 
sessile nature of skin resident effector 
memory T cells, as demonstrated in 
mice (Gebhardt et al., 2009). In con-
trast, malignant T cells in Sézary syn-
drome express CCR4 and the central 
memory markers L-selectin, CCR7, 
and CD27 but express variable lev-
els of the skin homing addressin CLA 
(Campbell et al., 2009). In this way, 
Sézary syndrome T cells resemble 
the 20% of T cells in normal skin that 
coexpress CLA, CCR4, L-selectin, and 
CCR7 (Clark et al., 2006). From what 
we understand of homing receptor 
expression, these T cells should be 
capable of entering and migrating 
through the blood, skin, and lymph 
nodes. Indeed, the malignant T cells 
in Sézary syndrome migrate through-
out the skin, producing erythroderma, 
and accumulate in the blood and 
lymph nodes.
Given this view of CTCL, it is logi-
cal that the Tregs in skin are equally 
vulnerable to malignant transforma-
tion. When this occurs, a malignancy 
of T cells is produced that may main-
tain the ability to suppress T-cell acti-
vation. Indeed, the suppressive char-
acteristics of Tregs may give lympho-
mas derived from these cells a survival 
advantage, allowing them to suppress 
tumor-specific cytotoxic T cells and 
thereby evade immune destruction. 
Infection is the most common cause of 
death in advanced-stage CTCL patients 
(Axelrod et al., 1992). In the subset of 
Sézary patients in whom malignant 
T cells are derived from the Treg lin-
eage, these cells may contribute to 
immune suppression. However, one 
does not have to invoke Treg-mediated 
suppression to explain the profound 
immune defects in patients with other 




subtypes of advanced CTCL. In most 
advanced-stage patients and even 
some with earlier stages, a profound 
loss of T-cell diversity and compen-
satory expansion of surviving clones 
is observed (Yamanaka et al., 2005; 
Yawalkar et al., 2003), suggesting 
widespread death of T cells on a par 
with that observed in HIV disease. 
T-cell losses of this magnitude repre-
sent a massive loss of critical immune 
memory accumulated over a lifetime 
of pathogen exposures. Why T-cell 
death is so widespread in CTCL, par-
ticularly in the subset of early-stage 
patients with limited skin disease, 
remains unknown.
Human skin is populated by a var-
ied collection of T cells with differing 
functional, proliferative, and migrato-
ry capacities. The diversity of clinical 
presentations in CTCL likely reflects 
the functional diversity of these T cells. 
Heid et al. (2009) have identified a 
Treg subtype of Sézary syndrome. As 
our understanding of both CTCL and 
normal skin T-cell biology improves, 
additional functional subtypes of 
CTCL will likely be identified (for 
example, Th17 or Th1 CTCL). In this 
way, we will move from a description 
of the reaction pattern (folliculotropic, 
granulomatous) to a description of 
the pathogenic T cell of origin. This 
improved understanding of the bio-
logy of malignant T cells will in turn 
allow us to tailor therapies to address 
the specific problems raised by each 
subtype. For example, therapies that 
suppress cytokine production and 
effector functions may be most appro-
priate in stable patch plaque mycosis 
fungoides, where malignant T cells 
make up a small but vocal minority of 
the T cells in skin lesions and primar-
ily cause trouble by engendering and 
supporting inflammation. In contrast, 
therapies that aim to kill malignant T 
cells may be advantageous in Sézary 
syndrome, where the problem is the 
sheer numbers of malignant T cells 
infiltrating the skin, blood, and lymph 
nodes and the resistance of these T 
cells to normal mechanisms of T-cell 
death. Until then, well-executed 
investigations such as the current study 
shed much needed light on the dimly 
lit field of CTCL immunobiology.
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